Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40p -3.29% 100.10p 100.50p 100.70p 103.40p 100.00p 103.40p 1,663,003 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 126.5 -40.1 -5.3 - 680.02

Vectura (VEC) Latest News (1)

More Vectura News
Vectura Takeover Rumours

Vectura (VEC) Share Charts

1 Year Vectura Chart

1 Year Vectura  Chart

1 Month Vectura Chart

1 Month Vectura  Chart

Intraday Vectura Chart

Intraday Vectura  Chart

Vectura (VEC) Discussions and Chat

Vectura Forums and Chat

Date Time Title Posts
21/9/201712:44Vectura - An emerging Pharmaceutical Co.6,000
04/4/200620:42A winner.87
04/4/200609:05VECTURA HAS 20M AND DEVELOPS DRUGS6

Add a New Thread

Vectura (VEC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:02:02101.2430,76331,144.19NT
15:44:50101.526,9857,091.50NT
15:35:18100.10211,574211,785.57UT
15:29:48100.502,1462,156.73AT
15:29:30100.605252.31AT
View all Vectura trades in real-time

Vectura (VEC) Top Chat Posts

DateSubject
21/9/2017
09:20
Vectura Daily Update: Vectura Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VEC. The last closing price for Vectura was 103.50p.
Vectura Group has a 4 week average price of 88.90p and a 12 week average price of 88.90p.
The 1 year high share price is 166.90p while the 1 year low share price is currently 88.90p.
There are currently 679,343,752 shares in issue and the average daily traded volume is 2,703,761 shares. The market capitalisation of Vectura Group is £680,023,095.75.
07/9/2017
12:56
0815exitstrategy: From the Telegraph.... Julie Simmonds, analyst at Panmure, commented that she believed the share price fall was an overreaction and said the firm would benefit from a trend towards more generic inhaler products and from further growth potential in Asia Pacific and Latin America. She added: “We see today’s fall as a good buying opportunity as the pipeline continues to progress to plan. “In our view the current share price attributes no value to the substantial and growing pipeline.”
29/8/2017
16:29
dunderheed: Its probably the skp mgt impact of joining the vec board that has caused this share price weakness?! Totally useless bunch of o/paid execs! I bought £20k recently for a 'tax free' isa bet having sold all my trading (turned long term!) shares last year. I'll never learn but luckily the tax losses have been useful to offset against ppty gains - thank god! Best of luck all!
25/5/2017
13:31
alex2727: Just back from AGM but, in brief, a very positive presentation. It seems Vec are more 'happy' with their result from the FDA than Mylan, because they have an issue with their device which Vec appears not to have. Vec/Hikma gave their response to the FDA within the requisite 10 days so it's now wait and see. It was stressed that the current 'disappointing' share price calculates, effectively, to the sum of the parts, and gives no value whatsoever to the pipeline or anything else. The board is very frustrated to say the least. The company is looking forward to their presentation on June 28th. I have a large holding in shares and spreads, and came away very comfortable to continue to hold all. That's it for now; I have a business to run. alex
25/4/2017
10:44
soundbuy: Well, this was from the 10th April Hikma Pharmaceuticals got a boost on Monday as Numis upgraded the stock to 'buy' from 'add'. It said that following Mylan’s Complete Response Letter, the market is now overly discounting Hikma’s prospects for gaining approval of its generic version of GlaxoSmithKline's bestselling asthma drug Advair this year. In addition, the share price is now also heavily discounting the core business, Numis said. "If Hikma gains FDA approval this year, most likely with minor deficiencies in a complete response letter, we see potential for a slight upgrade to our low-end FY17 forecasts, and a material upgrade to our low-end FY18 forecasts (potentially more than 10%), and envisage a higher multiple being warranted post upgrades (14x FY18 EV/EBITDA well underpinned versus peers)." Numis reckons Hikma has a stronger chance of approval than Mylan because it included 12-18 year olds in its study and has benefited from the expertise of Vectura, a business that, unlike Mylan, has a generic version of Advair Diskus approved in Europe in partnership with Sandoz. "In our opinion the current share price is well underpinned by the core business (more than 25% upside), with a free option on generic Advair. This is an asymmetric risk worth taking, with the catalyst now a month away and potential for more than 50% returns if Hikma's generic Advair is approved first time, or with minor deficiencies." In its final results on 15 March, Hikma said it expected revenue for the Generics business to be around $800m this year, with an improvement in the mix of sales and new product launches more than offsetting the impact of increased competition on the marketed portfolio and a reduction in contract manufacturing revenue. The group said certain new launches were expected to contribute around 15% of Generics revenue in 2017, primarily generic Advair, which was assumed to be launched in the second half of the year. Numis has a 2,350p price target on Hikma.
07/12/2016
07:07
gargoyle2: From another board: Vectura has transformed with Skyepharma, says Numis A merger with Skyepharma has had a transformative effect for biotech firm Vectura (VEC), according to Numis Securities. Analyst Stefan Hamill retained his ‘buy’ recommendation and target price of 252p on the stock, which slipped 1.6p or 1.1% to 138p yesterday.‘The transformative effects of the Skyepharma merger started to become clear at Vectura’s recent interims, with a significant step-up in revenues and underlying cashflow, an increase in the proportion of recurring revenues in the business, and underlying organic revenue growth strong at 305-plus driven by the ongoing global roll-out of seven inhalers containing Vectura technology,’ he said. With five potential new product launches in 2017, Hamill said he can ‘see Vectura sustaining its industry leading sales and profit growth over the next few years, propelling the share price’.
06/12/2016
08:38
robow: Vectura has transformed with Skyepharma says Numis A merger with Skyepharma has had a transformative effect for biotech firm Vectura (VEC), according to Numis Securities. Analyst Stefan Hamill retained his ‘buy’ recommendation and target price of 252p on the stock, which slipped 1.6p or 1.1% to 138p yesterday. ‘The transformative effects of the Skyepharma merger started to become clear at Vectura’s recent interims, with a significant step-up in revenues and underlying cashflow, an increase in the proportion of recurring revenues in the business, and underlying organic revenue growth strong at 305-plus driven by the ongoing global roll-out of seven inhalers containing Vectura technology,’ he said. With five potential new product launches in 2017, Hamill said he can ‘see Vectura sustaining its industry leading sales and profit growth over the next few years, propelling the share price’.
08/9/2016
14:50
rivaldo: Peel Hunt value VEC at 200p per share (BTW this article really needed sub-editing...): http ://www.proactiveinvestors.co.uk/companies/news/163605/this-unfancied-drug-stock-has-the-potential-to-soar-163605.html?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=7163-356640-Campaign+-+07%2F09%2F2016 "This unfancied drug stock has the potential to soar 14:38 07 Sep 2016 Peel Hunt’s Walker reckons Vectura is worth around 200p per share There is a huge opportunity for the likes Vectura and is partner Hikma Pharmaceuticals as they copy-cat GlaxoSmithKline's asthma treatment. They’ve been rewarded with an 11% rise in the share price post-results. But it has been a hard slog for investors in respiratory specialist Vectura Group PLC (LON:VEC), who have seen the stock drift by around a quarter over the last year. The reason for the decline? Well, according to analysts, there has been a degree of uncertainty around the £441mln takeover of Skyeparma, completed this summer. Earlier Vectura told the market the merger benefits would be higher than first anticipated. What followed was a relief rally; in other words, the markets concerns weren’t crystalised. So where to now for the stock? Well, according the broker Peel Hunt, the recent weakness of the share price provides an opportunity. Analyst Amy Walker says the company’s pipeline and technology platform is worth around 100p (or just over two-thirds of Vectura’s current valuation). That provides almost a “free option” on VR315, a generic version of Advair, the “mega blockbuster” asthma product developed by GlaxoSmithKline (LON:GSK). While Advair came off patent in 2010, it has remained uncontested until now because the delivery method retained patent protection. That final defence against the copy-cat producers has been eroded. In the first half Advair generated sales of £1.7bn for Europe’s largest pharma company. So there is a huge opportunity for the likes Vectura and is partner Hikma Pharmaceuticals (LON:HIK). Peel Hunt’s Walker reckons Vectura is worth around 200p per share, compared to a current market price of around 145p. The consensus valuation is 206p, based on NPVs provided four other brokers and the highest of those estimates is 231p. “Vectura has suffered a significant de-rating post the Skyepharma merger and recent disappointing news flow,” said “Our detailed analysis of the assumptions baked into the share price and consensus forecasts…suggest the stock now offers a free option on VR315 (generic Advair) on both a net present value and mid-term multiples basis.”"
29/3/2016
17:45
boadicea: Verger, I think your error is in the interpretation of your quote -"based on the VEC closing share price on 15/3/16 of 146.60p". That valuation is merely a statement of the share price at that time whereas the share swap is really based on the relative values of the two companies. On that basis, the market value of each company could be assumed to vary similarly with the market sentiment for the sector and the swap remains in a fair proportion. Or, trying to see it from your angle, since the proportion is virtually fixed (i.e.ignoring the cash element) the share price of SKP should rise at the same time and VEC get more SKP value for their "increased cost". As an interesting aside, the settlement of a part of the deal in cash is tantamount to a share buy-back because without it, i.e. in an all-paper deal, the number of shares being offered would have to be greater. So in effect, the company has repurchased (or avoided issuing) shares at the somewhat depressed price at the time of the deal and we have suffered less dilution. Two possible conclusions could be drawn from that action - 1) that there is unlikely to be a shortage of cash in the foreseeable future due to expectation of positive cash flows and 2) there is probably no early intention of a further major acquisition. The psychology of a cash element also raises the possibility that, with a bright future widely forecast for the combined entity, some of it may be ploughed back by recipients thereby either mopping up any prospective sells (e.g. by those who had a foot in both camps and who might now feel over-concentrated) or providing a demand which strengthens the share price
29/3/2016
13:20
verger: I'm confused! VEC have valued SKP as worth £x, and as it is a merger they have equated £x as a share swap ie 2.7977 VEC shares for every SKP share based on the VEC closing share price on 15/3/16 of 146.60p. If people think that SKP is worth more then the VEC share price needs to go up to reflect this. But what if people like the deal (as I do), buy into VEC pushing the share price up and making the deal more expensive for VEC? What is the timetable for this deal? Should they not suspend the shares? Or have I missed something? Advice please!
24/3/2016
12:08
soundbuy: H/T FT AV Numis The union of Vectura and Skyepharma is one of the most complementary mergers in the UK healthcare sector. It will create a £1bn+ FTSE250 UK respiratory champion with strong, globally competitive technologies and capabilities across the entire spectrum of dry powder, smart nebuliser and now metered dose inhalers, making it the partner of choice in targeting the airways and allowing it to address 60% more of the $35bn global respiratory market than Vectura did on its own. We see the merger as a strategically and financially logical step-up for Vectura, with the combined company offering critical mass and attractive growth at a good price. We re-introduce our Buy recommendation with a 12-month target of 264p. ● In this 30-page note, we look at Skyepharma in some detail, focusing on Flutiform in particular. We see the prospect of it becoming a c.$500m drug as realistic, offering Vectura shareholders a growing, lower risk cash flow to diversify its higher risk prospects (VR315 and wholly owned FAVOLIR / SCIPE assets). ● The ongoing roll-out of Flutiform is set to transform the P&L with revenues and underlying EBITDA set to approximately double and then grow at 14% and 20% CAGR respectively to end FY2021. EPS CAGR is higher, at 33%. ● We see EPS accretion of 24% in year 1 (FY2017, 7% ROI), growing to c.60% over years 2-3 (FY2018-2019, double digit ROI), then falling to single digits as VR315 royalties come through and are spread over a higher share count. ● The deal washes its face on our risk-adjusted SOTP analysis (£470m vs £460m consideration and estimated costs). ● Our risk adjusted SOTP value is 14% diluted from our previous 271p target. The potential for platform synergies are not captured in this approach, which to date has attributed no terminal value to the assets. ● Skyepharma will bring in significant near-term cash-flows to give management a multitude of options to make the leap to self-commercialisation and build lasting sustainable enterprise value. The time feels right to switch to a multiple-based valuation. ● We see the increased size, liquidity and FTSE250 listing increasing awareness of Vectura's steep forecast trajectory. A rating relative to BTG feels appropriate. Applying a P/E in line with BTG of 24.7x (vs 29% risked EPS CAGR) our risked FY2020 EPS of 16.8p (fully taxed) and discounting back, we see a multiples based valuation of 294p. We blend this with our SOTP of 234p to derive our target price of 264p, reflecting the need to complete the transition to self commercialisation. ● On our initial projected consolidated EPS forecasts, Vectura's P/E drops to single digits by year 3 (FY2019), now driven mostly by Flutiform: a strong buy signal in our view. RBC Cap Mkts. Strategic rationale: Strategically, we see the deal enhancing Vectura’s capabilities (oral, pMDI and commercial manufacturing) but think the financial rationale is the main motive for the combination. Vectura has a larger pipeline but its partnered assets have only recently launched and its financial profile still less developed than SKP’s, which has a smaller pipeline but with key assets launched and delivering profit growth (FY15A EBITDA margin of 37.5%). Combined, we see the two offering a healthy pipeline of opportunities with a strong financial profile. Turbo charged financials: We choose not to update our forecasts (or valuation) until completion of the deal and instead provide a view on the combination below and within the note. The New Co will have an implied Mcap of £1.1bn and offer a revenue, EBITDA and EPS 3-year CAGR (FY17E-20E) of 31.7%, 41.3% and 32.1% respectively with a FCF yield of c10%. More importantly, the Group will become attactive on conventional multiple metrics, PE of 12.6x FY18E EPS (March YE) given the earnings ramp delivered by SKP. Valuation mixed: We think Vectura have paid a fair but full price for SKP which, when executed alongside recent share price weakness has magnified the potential dilution. That said, we acknowledge that acquisition targets that fit well rarely coincide with perfect market conditions. Our conventional valuation for Vectura (SoTP; DCF and rNPV) suggests fair value of New Co at c190p (down from 206p) once the deal completes. However, we think investors should focus on the New Co financial profile which shows the shares trading on an implied EV/EBITDA of sub 10x by FY18E and 12.6x FY18E EPS. Considering upcoming newsflow (VR315 in particular) alongside growth and cash generation metrics we believe a re-rating likely from these low levels given the growth on offer. Valuation: Given the risk associated with assets not yet approved by regulators or still in their launch phase we utilise a SoTP model; for partnered launched assets we utilise NPV analysis with a WACC rate of 7% (Vectura is net cash) and no terminal value beyond Vectura’s patent protection. For partnered pipeline assets we use risk-adjusted NPVs with a discount rate of 10%, standard industry associated risk adjustments and no terminal value beyond Vectura’s patent protection on the products. For wholly owned pipeline assets we also use a rNPV (again a discount rate of 10% and standard risk adjustments) but apply a terminal with a growth rate of -2.5%. This provides our price target of 205p and our Outperform rating, although near term newsflow on VR315 in the US and on both Utibron & Seebri assets (also US) may drive our valuation towards 230p. We have not updated our forecasts or valuation for the SKP merger, but provide sensitivity analysis to our forecasts and valuation within. Price target impediments: We see two key impediments to our price target and rating: 1. VR315 – The launch of VR315 in the US is arguably the most important launch from Vectura’s pipeline over the coming months. A generic of Advair (aka Seretide) we anticipate the product being directly substitutable and, with only one competitor (Mylan) in the short term we have modelled only partial price erosion. If this launch is delayed then this would erode an estimated c7p for each 6 month delay and we see downside risk as capped at c.50p to our valuation if the product fails to launch altogether. 2. Utibron & Seebri – Whilst we believe Novartis is unlikely to shelve these assets in the US, it could find a commercial partner given the cost of launching and as the market becomes more competitive. We see downside risk of c.20p to our valuation if the assets are not launched in the US.
Vectura share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170921 21:31:30